Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Long-term reserpine use in selected refractory outpatients.

Bacher N, Lewis HA.

Am J Psychiatry. 1985 Mar;142(3):386-7. No abstract available.

PMID:
2857536
2.

Addition of reserpine to antipsychotic medication in refractory chronic schizophrenic outpatients.

Bacher NM, Lewis HA.

Am J Psychiatry. 1978 Apr;135(4):488-9. No abstract available.

PMID:
25024
3.

Neuroleptics and reserpine in refractory psychoses.

Berlant JL.

J Clin Psychopharmacol. 1986 Jun;6(3):180-4.

PMID:
2872238
4.
5.

Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study.

Treuer T, Martenyi F, Saylan M, Dyachkova Y.

Int J Clin Pract. 2010 May;64(6):697-706. doi: 10.1111/j.1742-1241.2009.02331.x. Epub 2010 Mar 16. Erratum in: Int J Clin Pract. 2010 Sep;64(10):1459.

PMID:
20345873
7.

High-dose antipsychotic medication.

Bennie EH.

Br J Psychiatry. 1994 Oct;165(4):553. No abstract available.

PMID:
7528625
8.

Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.

Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, Edgell ET, Ratcliffe M; SOHO Advisory Board.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):972-82.

PMID:
16023776
9.

Reserpine added to neuroleptic-tricyclic in refractory schizophrenics.

Bacher N, Lewis H.

J Clin Psychiatry. 1981 Aug;42(8):326. No abstract available.

PMID:
7019202
10.

Metabolic syndrome in patients with schizophrenia.

Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J.

J Clin Psychiatry. 2003 May;64(5):575-9.

PMID:
12755662
11.

Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.

Arango C, Kirkpatrick B, Buchanan RW.

J Nerv Ment Dis. 2000 Jan;188(1):50-3. No abstract available.

PMID:
10665462
12.

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V.

J Psychopharmacol. 2006 Nov;20(6):829-33. Epub 2006 Feb 14.

PMID:
16478753
13.

Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia.

Perenyi A, Goswani U, Bela A, Freoska E, Arato M, Hegedus I.

Schizophr Res. 1988 Jul-Aug;1(4):307-8. No abstract available.

PMID:
2908704
14.

Addition of lithium to neuroleptic treatment in chronic schizophrenia.

Lewis HA, Bacher NM, Field PB.

Am J Psychiatry. 1986 Feb;143(2):262. No abstract available.

PMID:
2868667
15.

[Long-term treatment of outpatients with depot neuroleptics (author's transl)].

Saameli W.

Schweiz Rundsch Med Prax. 1981 Feb 3;70(6):206-10. German. No abstract available.

PMID:
6113584
16.

Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.

Faraone SV, Brown WA, Laughren TP.

J Clin Psychiatry. 1987 Apr;48(4):151-4.

PMID:
2881923
17.

Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.

Salvesen C, Vaksdal K.

Behav Neuropsychiatry. 1973 Oct-1974 Mar;5(7-12):3-7. No abstract available.

PMID:
4154740
18.

[Psychomotor performance of schizophrenic patients and long-term neuroleptic therapy].

Burr W, Kaiser E.

Psychiatr Clin (Basel). 1983;16(5-6):316-23. German.

PMID:
6139845
19.

[An attempt to discontinue long-term psychopharmacologic therapy in chronic schizophrenics].

Klik J, Fait V, Bat'ková Z.

Cesk Psychiatr. 1984 Apr;80(2):121-4. Czech. No abstract available.

PMID:
6147204
20.

Clinical and social correlates with the use of depot antipsychotic drugs in outpatients with schizophrenia in China.

Xiang YT, Weng YZ, Leung CM, Tang WK, Ungvari GS.

Int J Clin Pharmacol Ther. 2008 May;46(5):245-51.

PMID:
18538110

Supplemental Content

Support Center